Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

Estimize Aug. 4 at 12:03 PM

Wall St is expecting -0.72 EPS for $VIR Q3 [Reporting 10/30 AMC] http://www.estimize.com/intro/vir?chart=historical&metric_name=eps&utm_con

0 · Reply

VIR_Tical1 Jul. 31 at 1:50 PM

$VIR * First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite bulevirtide treatment * ECLIPSE 2 is a pivotal trial designed to support global marketing applications, including in the U.S. and Europe

0 · Reply

VIR_Tical1 Jul. 31 at 1:41 PM

$VIR Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

0 · Reply

Pharm_Hand Jul. 25 at 7:08 PM

$VIR 425 more shares today at the $5.63 low.

0 · Reply

Dunnieboy1 Jul. 24 at 12:20 PM

$VIR SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal growth factor receptor). VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and cutaneous squamous cell carcinoma (cSCC).

0 · Reply

Dunnieboy1 Jul. 24 at 12:18 PM

$VIR Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such as NSCLC, CRC, HNSCC and cSCC VIR-5525, the Company’s third dual-masked T-cell engager leveraging the PRO-XTEN™ technology, is designed to expand the therapeutic index by selectively activating in the tumor microenvironment Dose escalation continues for Phase 1 studies of PRO-XTEN™ dual-masked TCEs VIR-5818 (HER2) and VIR-5500 (PSMA), with compelling early clinical response signals and promising safety profiles

0 · Reply

Dunnieboy1 Jul. 24 at 12:11 PM

$VIR at last we’ve announced the new trial has begun;Vir Biotechnology - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

1 · Reply

BASEflyer Jul. 23 at 8:01 PM

$VIR someone loading at closing

1 · Reply

BASEflyer Jul. 23 at 5:32 PM

$IOVA nice move today 🥳 $VIR will be next 100% gainer 🚀🚀🚀 LFG

0 · Reply

Dunnieboy1 Jul. 23 at 6:07 AM

$VIR Vir Biotechnology, Inc. (VIR, Financial) to announce Q2 2025 financial results on August 6, 2025. Conference call scheduled at 1:30 p.m. PT/4:30 p.m. ET on the same day. Focus on infectious diseases and cancer with a robust clinical-stage portfolio.

0 · Reply

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 11 days ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 23, 2025, 12:10 PM EDT - 12 days ago

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 22, 2025, 4:05 PM EDT - 13 days ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 7 weeks ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 3 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025, 3:37 PM EDT - 3 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 7, 2025, 11:21 PM EDT - 3 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 3 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 4 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 5 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 11:22 PM EST - 5 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 5 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 5 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 13, 2025, 6:10 PM EST - 7 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 7 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 7 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 7 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 7 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 8 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 8 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 8 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 8 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 9 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 9 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 9 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024, 11:00 AM EST - 9 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 5, 2024, 11:29 AM EST - 9 months ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Oct 31, 2024, 11:12 PM EDT - 9 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 9 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 17, 2024, 4:30 PM EDT - 10 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 15, 2024, 8:16 AM EDT - 10 months ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 3, 2024, 4:00 PM EDT - 10 months ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:05 AM EDT - 11 months ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 9, 2024, 4:05 PM EDT - 11 months ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Aug 22, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 10:10 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:02 PM EDT - 1 year ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 17, 2024, 4:47 PM EDT - 1 year ago

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jun 26, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Jun 5, 2024, 5:30 AM EDT - 1 year ago

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

May 29, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Estimize Aug. 4 at 12:03 PM

Wall St is expecting -0.72 EPS for $VIR Q3 [Reporting 10/30 AMC] http://www.estimize.com/intro/vir?chart=historical&metric_name=eps&utm_con

0 · Reply

VIR_Tical1 Jul. 31 at 1:50 PM

0 · Reply

VIR_Tical1 Jul. 31 at 1:41 PM

$VIR Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

0 · Reply

Pharm_Hand Jul. 25 at 7:08 PM

$VIR 425 more shares today at the $5.63 low.

0 · Reply

Dunnieboy1 Jul. 24 at 12:20 PM

0 · Reply

Dunnieboy1 Jul. 24 at 12:18 PM

0 · Reply

Dunnieboy1 Jul. 24 at 12:11 PM

1 · Reply

BASEflyer Jul. 23 at 8:01 PM

$VIR someone loading at closing

1 · Reply

BASEflyer Jul. 23 at 5:32 PM

$IOVA nice move today 🥳 $VIR will be next 100% gainer 🚀🚀🚀 LFG

0 · Reply

Dunnieboy1 Jul. 23 at 6:07 AM

0 · Reply

BASEflyer Jul. 21 at 8:58 PM

$VIR thats crazy how they pump it to$6 and then bleed back to $5.52

2 · Reply

Shelz912 Jul. 21 at 8:26 PM

$VIR - What happened to the revenue?

2 · Reply

BASEflyer Jul. 21 at 2:03 PM

$VIR she is alive again 🔥

0 · Reply

StocksNCash Jul. 19 at 3:57 PM

Looking for some positive moves next week: $CRBU $PRME $VIR $HIVE $IGC

0 · Reply

Michelehuanga Jul. 19 at 4:41 AM

$VIR just cleared a big level. Watching for continuation.

1 · Reply

Mhand Jul. 18 at 6:58 PM

$VIR Here's the biggest driver of our share price. Options are a total scam. Especially for easily manipulated small caps like VIR.

0 · Reply

BASEflyer Jul. 16 at 7:19 PM

I’m in $IOVA and $VIR supper bullish on those 2 companies!

1 · Reply

Dunnieboy1 Jul. 15 at 6:31 PM

$VIR down over 5% today, we have lost the 11% gain from last week.

2 · Reply

BASEflyer Jul. 15 at 2:57 PM

$VIR i thought we suppose o have an update in H1? 🤔

1 · Reply

BASEflyer Jul. 11 at 2:56 PM

$VIR lol down almost 5% with 250k volume 🤣🤣🤣

0 · Reply

JarvisFlow Jul. 11 at 1:05 PM

Raymond James has updated their rating for Vir Biotechnology ( $VIR ) to Outperform with a price target of 12.

1 · Reply

Dunnieboy1 Jul. 11 at 12:01 PM

$VIR Vir Biotechnology, Inc. VIR shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks. The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a registrational phase III ECLIPSE 1 study for treating chronic hepatitis delta (CHD). VIR is also gearing up to initiate a phase III ECLIPSE 2 study to assess the efficacy and safety of switching to tobevibart and elebsiran in individuals with CHD who have not achieved viral suppression with bulevirtide treatment.

1 · Reply

Market Cap	695.34M
Revenue (ttm)	74.21M
Net Income (ttm)	-521.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-703.36%
Debt to Equity Ratio	0.00

Volume	934,400
Avg Vol	1,201,148
Day's Range	N/A - N/A
Shares Out	138.24M
Stochastic %K	14%
Beta	1.18
Analysts	Strong Sell
Price Target	$17.62